SECsense Logo

Agios Pharmaceuticals 8-K Report: Key Disclosure on January 3, 2025

$AGIO
Form 8-K
Filed on: 2025-01-06
Source
Agios Pharmaceuticals 8-K Report: Key Disclosure on January 3, 2025

Here is the extracted key information and insights from the provided section of the financial report:

  1. Entity Information:
  • Company Name: Agios Pharmaceuticals, Inc.
  • CIK (Central Index Key): 0001439222
  • State of Incorporation: Delaware (DE)
  • IRS Employer Identification Number (EIN): 26-0662915
  • Address: 88 Sidney Street, Cambridge, MA 02139
  • Phone Number: (617) 649-8600
  1. Filing Details:
  • Filing Type: 8-K
  • Filing Date: January 3, 2025
  • Period of Reporting: January 3, 2025 (indicating a specific event or information disclosure on that date)
  1. Stock Information:
  • Common Stock Information:
    • Par Value: $0.001 per share
    • Ticker Symbol: AGIO
    • Exchange: NASDAQ
  1. Context Information:
  • Duration of Context: The context indicates that the reporting period is a single day, January 3, 2025.

Insights:

  • The report is a Form 8-K, which typically indicates that the company is disclosing material events or corporate changes that shareholders should be aware of.
  • The specific reporting date of January 3, 2025, suggests that any events disclosed could be time-sensitive and relevant to shareholders or potential investors.
  • The inclusion of the stock details indicates that Agios Pharmaceuticals is publicly traded, and the information may impact its stock performance or investor perception.

This information is crucial for stakeholders, including investors, analysts, and regulatory bodies, for assessing the company's current situation and any potential implications related to its operations or market performance.